M12 co-led a $22m series A round for the drug discovery technology developer with Playground Global, and both investors have taken board seats.
US-based drug development technology developer 1910 Genetics emerged from stealth yesterday having completed a $22m series A round featuring software producer Microsoft’s corporate venturing unit, M12. Venture capital firm Playground Global co-led the round, which followed a $4.1m seed round led by Sam Altman and backed by fellow angel investors including Tuck Lye Koh as…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.